University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

What University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center does

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is an NCI-designated comprehensive cancer center within the University of Maryland Medical Center and University of Maryland Medical System in Baltimore, operating in partnership with the University of Maryland School of Medicine. It delivers multidisciplinary cancer treatment, including surgery, radiation, chemotherapy, immunotherapy, cellular therapies (CAR T-cell and TCR-T), and MRI-guided focused ultrasound for blood-brain barrier opening, alongside an active clinical trials program and telehealth services. UMGCCC treats patients across all cancer types and operates five research programs (Cancer Biology, Cancer Therapeutics, Population Science, Tumor Immunology and Immunoengineering, and Experimental Therapeutics/Hormone Related Cancers) and eight shared resource facilities (Biostatistics, Genomics, Flow Cytometry, Imaging, Pathology, etc.), supported by training pipelines from middle school through postdoctoral levels.

The center's technology platform integrates cellular immunotherapy manufacturing capabilities, MRI-guided focused ultrasound (delivered via Insightec devices), CRISPR-mediated gene editing combined with machine learning for gene function modeling, radiomics for treatment response prediction, and spatial transcriptomics with computational digital twin simulation. It maintains multi-institutional research collaborations with Johns Hopkins, MD Anderson, Brigham and Women's Hospital, the ReFOCUSED focused ultrasound consortium (20+ sites), and ECOG-ACRIN. Revenue is generated through clinical care delivery (hospital billing and insurance reimbursement), federal research grants (NCI Cancer Center Support Grant P30CA134274, NCI Career Development Awards, SPORE grants), public-private partnerships (notably AstraZeneca for lung cancer screening), and philanthropy (including a $5.5 million Greenebaum family donation).

Name

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Legal name

University of Maryland Medical Center (UMMC)

Website

https://umgccc.org

Company type

Private

Founded year

2024

Operating status

Operating

Short description

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is an NCI-designated comprehensive cancer center in Baltimore that delivers multidisciplinary cancer treatment, cellular immunotherapy, and MRI-guided focused ultrasound, alongside an active clinical trials and research program serving patients across the Maryland, Delaware, Virginia, and Washington D.C. region.

Ownership category

akta.pro rank

Product category

Comprehensive Cancer Center

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Scientific Research and Development Services (5417)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Oncology Telemedicine Platforms (HLALAGAH), Neuro-Oncology (HLAKAFAH), Gynecologic Oncology (HLAKAFAF)

Keywords

• Cancer treatment services
• Cellular immunotherapy
• Clinical research trials
• Radiation oncology
• Precision medicine

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Care and Treatment Services: As an academic medical center cancer center within the University of Maryland Medical Center and Medical System, UMGCCC generates revenue through providing multidisciplinary cancer treatment services including surgery, chemotherapy, radiation therapy, cellular immunotherapy, and clinical trial treatments to patients.
2. Federal Research Grants (NCI, NIH): Receives federal funding through NCI Cancer Center Support Grant (P30CA134274), NCI Career Development Awards ($3 million ARCH K12 Program), SPORE grants, and other NIH funding to support basic science, translational, and clinical research programs.
3. Philanthropy and Donations: The Greenebaum family donated $5.5 million to advance cancer research and patient care. The center receives charitable donations through its giving program.
4. Public-Private Partnerships: Secured an $8 million public-private partnership with AstraZeneca to provide greater access to lung cancer screening throughout Maryland.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Core offering

UMGCCC is an NCI-designated comprehensive cancer center that delivers multidisciplinary cancer diagnosis, treatment, and survivorship care to patients, including surgery, chemotherapy, radiation therapy, cellular immunotherapy (CAR T-cell and TCR-T therapies), and MRI-guided focused ultrasound for brain tumors. The center runs an extensive clinical trials portfolio, five cancer research programs, eight shared resource cores, and training/education programs from middle school through postdoctoral levels. Patient services are supplemented by telehealth, support services, and community outreach within the Maryland catchment area.

Product overview

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is an NCI-designated comprehensive cancer center offering a fully integrated portfolio of cancer care services and research programs. The core patient-facing offerings include multidisciplinary cancer treatment (surgery, radiation, chemotherapy, immunotherapy, targeted therapy), cellular therapies (CAR T-cell and TCR-T), and focused ultrasound for brain tumors, complemented by an active clinical trials program and telehealth services. Behind the clinical services, the center operates extensive research infrastructure including five research programs (Cancer Biology, Cancer Therapeutics, Population Science, Tumor Immunology and Immunoengineering, Experimental Therapeutics, Hormone Related Cancers), eight shared resource facilities (Biostatistics, Genomics, Flow Cytometry, Imaging, Pathology, etc.), and comprehensive training/education from K-12 through postdoctoral levels. The institution ranks among the top 50 cancer programs nationally (US News & World Report) and is the first in the Mid-Atlantic region to offer innovative cell therapies like TCR-T for solid tumors.

Differentiator

Problem solved

Functional benefit

Brands

• ARCH K12 Program: Advancing Oncologic Research Communities in Health Equity program - NCI Career Development Award program to train next generation of oncology researchers
• Nathan Schnaper Intern Program (NSIP)
• CURE Scholars Program
• RAMP Program

Products and services

• Cancer Treatment Services Multidisciplinary cancer treatment including surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapies for all cancer types. Includes outpatient care, inpatient services, and supportive care for individual cancer patients.
• Clinical Trials Active clinical research program offering patients access to experimental therapies including cell therapies (CAR T-cell, TCR-T), focused ultrasound treatments, and novel drug trials across various cancer types.
• Telehealth Services Remote patient consultation and follow-up services enabling geographic access to cutting-edge cancer care, second opinions, and ongoing treatment management for patients beyond the Baltimore campus.
• TCR-T Therapy for Synovial Sarcoma FDA-approved T-cell receptor-engineered T-cell therapy that extracts a patient's T-cells, genetically engineers them to recognize intracellular cancer antigens, and re-infuses them to target and destroy tumor cells, specifically for synovial sarcoma patients.
• CAR T-cell Therapy Cellular immunotherapy that engineers a patient's own T-cells to recognize and attack cancer cells, with ongoing research to improve effectiveness through novel targets like cathepsin B for patients with recurrent or difficult-to-treat blood cancers.
• MRI-guided Focused Ultrasound for Glioblastoma

Quantifiable outcome

• Glioblastoma patients receiving focused ultrasound with chemotherapy showed nearly 40% increase in overall survival: median 30+ months vs 19 months for control group; median progression-free survival of 14 months vs 8 months for control.
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered major and core.

• AstraZenecamajorStrategic or Co-development Partner · 1 April 2024UMGCCC secured an $8 million public-private partnership with AstraZeneca to provide greater access to lung cancer screening throughout Maryland. This partnership represents a significant public health initiative to improve early detection of lung cancer in the state.
• Van Andel Institute Stand Up to Cancer Epigenetics Dream TeammajorStrategic or Co-development Partner · 1 January 2021SPORE grant funding (estimated $12.4 million over five years) awarded to The Coriell Institute for Medical Research and Van Andel Institute supporting epigenetic therapies research involving UMGCCC.
• Insightec Inc.coreTechnology or IntegrationInsightec Inc. is the device manufacturer providing the MRI-guided focused ultrasound technology used in UMGCCC's landmark glioblastoma trial. The company funded the clinical trial and provides the specialized equipment for blood-brain barrier opening procedures.
• ReFOCUSED (Research Consortium for Transcranial Focused UltraSound-Enhanced Drug Delivery & Diagnostics)majorStrategic or Co-development PartnerGrowing consortium of researchers from over 20 sites across North America working to advance MRI-guided focused ultrasound for brain diseases. UMGCCC's Dr. Woodworth co-leads the LIBERATE pivotal trial through this consortium.
• University of Toronto, Harvard University, University of Virginia, West Virginia UniversitymajorStrategic or Co-development PartnerFour additional clinical trial sites affiliated with UMGCCC's landmark focused ultrasound trial, demonstrating multi-institutional collaboration for glioblastoma research.
• Indiana University School of Medicine-BloomingtonmajorStrategic or Co-development PartnerCo-led the ZNFX1 master regulator gene study for ovarian cancer alongside UMSOM and Johns Hopkins University. Six institutions total collaborating on the SPORE grant-funded research.
• Johns Hopkins University School of MedicinemajorStrategic or Co-development PartnerCo-led ovarian cancer ZNFX1 research with UMSOM. Additional collaboration on cancer cell behavior simulation software with IGS team contribution to computational modeling research.
• MD Anderson Cancer CentermajorStrategic or Co-development PartnerContributed 77 patients to the radiomics study on head and neck squamous cell carcinoma alongside 203 patients from UMGCCC, dating back to 2003.
• Brigham and Women's HospitalmajorStrategic or Co-development PartnerLongstanding collaboration on focused ultrasound blood-brain barrier research. Dr. Alexandra J. Golby from Brigham and Women's co-authored the acoustic emissions study building on seminal work from the 1990s at that institution.
• ECOG-ACRIN Cancer Research GroupmajorStrategic or Co-development PartnerNCI National Clinical Trials Network member group through which UMGCCC researchers led the AML survival disparities study analyzing data from 3,469 white patients and 184 Black patients across 10 clinical trials from 1984-2019.
• University of Maryland Institute for Genome Sciences (IGS)coreStrategic or Co-development PartnerCore research partner within UMSOM providing genomics, bioinformatics, and computational biology capabilities. Dr. Elana Fertig serves as Director of IGS and Associate Director for Quantitative Science at UMGCCC.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Abramson Cancer Center at the University of Pennsylvania: NCI-designated comprehensive cancer center within an academic medical system, with deep programs in CAR-T cell therapy (a generationally important player in cellular immunotherapy) and translational research comparable to UMGCCC's portfolio.
• Dana-Farber Cancer Institute: Harvard-affiliated NCI-designated comprehensive cancer center and one of the leading oncology research and treatment institutions nationally, with comparable cellular therapy and translational research programs.
• UPMC Hillman Cancer Center: NCI-designated comprehensive cancer center within a major academic medical system in Pittsburgh, with broad translational and clinical research programs directly analogous to UMGCCC's research structure.
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: NCI-designated comprehensive cancer center operating in Baltimore as UMGCCC's closest direct peer. Both run multidisciplinary oncology programs, share the mid-Atlantic patient pool, and collaborate on ZNFX1 ovarian cancer research and computational genomics through IGS.
• Roswell Park Comprehensive Cancer Center: One of the original NCI-designated comprehensive cancer centers with deep cellular therapy, translational research, and surgical oncology programs. Comparable scale and academic integration profile to UMGCCC.
• Winship Cancer Institute of Emory University: NCI-designated comprehensive cancer center with strong translational research, cellular immunotherapy, and population science programs comparable in scope and academic-medical-center integration to UMGCCC.

Regional players

• Georgetown Lombardi Comprehensive Cancer Center: NCI-designated comprehensive cancer center serving the Washington D.C. region — the same mid-Atlantic geography as UMGCCC. Competes directly for regional oncology referrals, trial enrollment, and oncology faculty.
• VCU Massey Comprehensive Cancer Center: NCI-designated comprehensive cancer center based in Richmond, Virginia — part of UMGCCC's target catchment region. Competes for mid-Atlantic patients and federal grant funding pools.

Broad incumbents

• University of Texas MD Anderson Cancer Center: The largest NCI-designated comprehensive cancer center in the US and the long-standing national benchmark. Contributed 77 patients to UMGCCC's head-and-neck radiomics study and competes with UMGCCC in rare-cancer trial referrals.
• Memorial Sloan Kettering Cancer Center: Top national NCI-designated comprehensive cancer center with flagship programs in cellular immunotherapy, surgical oncology, and translational research. Dr. Jeremy Davis (UMGCCC's new Surgical Oncology Lead) completed a complex general surgical oncology fellowship there.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/umms
• YouTubeyoutube.com/watch?v=XfwUYUJeSi0&list=PLCgtJxzC5vXbO9KsONM6u3oXyOAmyxwyz
• Facebookfacebook.com/UMGCCC
• LinkedInlinkedin.com/company/university-of-maryland-greenebaum-comprehensive-cancer-center

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center